糖尿病：最新进展与未来展望
Diabetes: Recent Advances and Future Perspectives.
作者信息
Janić Miodrag, Janež Andrej, El-Tanani Mohamed, Maggio Viviana, Rizzo Manfredi
机构信息
Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
出版信息
Biomedicines. 2024 Dec 18;12(12):2875. doi: 10.3390/biomedicines12122875.
Abstract
Diabetes is a chronic metabolic disorder distinguished by persistent hyperglycemia [...].
摘要
糖尿病是一种以持续性高血糖为特征的慢性代谢紊乱疾病[……]。
相似文献
1
Diabetes: Recent Advances and Future Perspectives.糖尿病：最新进展与未来展望
Biomedicines. 2024 Dec 18;12(12):2875. doi: 10.3390/biomedicines12122875.
2
Immune-Mediated Ocular Surface Disease in Diabetes Mellitus-Clinical Perspectives and Treatment: A Narrative Review.糖尿病中的免疫介导性眼表疾病——临床观点与治疗：一项叙述性综述
Biomedicines. 2024 Jun 12;12(6):1303. doi: 10.3390/biomedicines12061303.
3
Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives.2型糖尿病及其相关并发症病理生理学中的氧化应激：当前治疗策略与未来展望
Free Radic Biol Med. 2022 May 1;184:114-134. doi: 10.1016/j.freeradbiomed.2022.03.019. Epub 2022 Apr 7.
4
Regulation of Hepatic Metabolism, Recent Advances, and Future Perspectives.肝脏代谢的调控：最新进展与未来展望。
Curr Diab Rep. 2019 Sep 7;19(10):98. doi: 10.1007/s11892-019-1224-4.
5
Management of Microcomplications of Diabetes Mellitus: Challenges, Current Trends, and Future Perspectives in Treatment.糖尿病微血管并发症的管理：治疗中的挑战、当前趋势及未来展望
Biomedicines. 2024 Aug 28;12(9):1958. doi: 10.3390/biomedicines12091958.
6
Diabetic Wound-Healing Science.糖尿病创面愈合科学。
Medicina (Kaunas). 2021 Oct 8;57(10):1072. doi: 10.3390/medicina57101072.
7
Therapeutic Potentials of Microalgae and Their Bioactive Compounds on Diabetes Mellitus.微藻及其生物活性化合物对糖尿病的治疗潜力
Mar Drugs. 2023 Aug 23;21(9):462. doi: 10.3390/md21090462.
8
Specialized pro-resolving mediators in diabetes: novel therapeutic strategies.糖尿病中的特异性促解决介质：新型治疗策略。
Clin Sci (Lond). 2019 Nov 15;133(21):2121-2141. doi: 10.1042/CS20190067.
9
[Diabetes mellitus: clinical presentation and differential diagnosis of hyperglycemia in childhood and adolescence].[糖尿病：儿童及青少年高血糖的临床表现与鉴别诊断]
An Pediatr (Barc). 2012 Nov;77(5):344.e1-344.e16. doi: 10.1016/j.anpedi.2012.06.013. Epub 2012 Aug 1.
10
β-Cell Death in Diabetes: Past Discoveries, Present Understanding, and Potential Future Advances.糖尿病中的β细胞死亡：过去的发现、当前的认识及未来潜在进展
Metabolites. 2021 Nov 22;11(11):796. doi: 10.3390/metabo11110796.
引用本文的文献
1
Adolescent Obesity in India: Need for Urgent Policy Action and Multi-sectoral Reform.印度青少年肥胖问题：迫切需要政策行动和多部门改革。
Indian J Endocrinol Metab. 2025 Mar-Apr;29(2):131-132. doi: 10.4103/ijem.ijem_172_25. Epub 2025 Apr 29.
本文引用的文献
1
Glucagon-like Peptide-1 Receptor Agonist Use in Hospital: A Multicentre Observational Study.胰高血糖素样肽-1受体激动剂在医院中的应用：一项多中心观察性研究
Can J Diabetes. 2025 Feb;49(1):37-43. doi: 10.1016/j.jcjd.2024.10.011. Epub 2024 Oct 30.
2
Young adult-onset type 2 diabetes heralds a poor prognosis.青年成人发病的2型糖尿病预示着预后不良。
Lancet Diabetes Endocrinol. 2024 Dec;12(12):869-870. doi: 10.1016/S2213-8587(24)00282-1. Epub 2024 Oct 23.
3
GLP-1 Receptor Agonist and SGLT2 Inhibitor Prescribing in People With Type 1 Diabetes.1型糖尿病患者中胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂的处方情况
JAMA. 2024 Nov 19;332(19):1667-1669. doi: 10.1001/jama.2024.18581.
4
When Does Metabolic Memory Start? Insights From the Association of Medical Diabetologists Annals Initiative on Stringent HbA1c Targets.代谢记忆何时开始？来自糖尿病专科医生协会《关于严格糖化血红蛋白目标的年度倡议》的见解。
Diabetes. 2025 Jan 1;74(1):75-81. doi: 10.2337/db24-0166.
5
Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation.恩格列净与达格列净治疗成年 2 型糖尿病患者的心血管有效性比较：一项模拟目标试验。
Circulation. 2024 Oct 29;150(18):1401-1411. doi: 10.1161/CIRCULATIONAHA.124.068613. Epub 2024 Aug 29.
6
Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes.在 2 型糖尿病患者中，替西帕肽或 GLP-1 受体激动剂的临床结局。
JAMA Netw Open. 2024 Aug 1;7(8):e2427258. doi: 10.1001/jamanetworkopen.2024.27258.
7
Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus.了解恩格列净对2型糖尿病患者心肾保护作用的介导机制。
J Diabetes Complications. 2023 Dec;37(12):108630. doi: 10.1016/j.jdiacomp.2023.108630. Epub 2023 Oct 23.
8
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group.心脏代谢连续体的现代管理：从超重/肥胖到糖尿病前期/2型糖尿病。东欧和南欧糖尿病与肥胖专家组的建议。
Diabetes Ther. 2024 Sep;15(9):1865-1892. doi: 10.1007/s13300-024-01615-5. Epub 2024 Jul 11.
9
Achievement of normoglycemia with tirzepatide in type 2 diabetes mellitus: A step closer to drug-induced diabetes remission?在 2 型糖尿病中使用替尔泊肽实现血糖正常化：更接近药物诱导的糖尿病缓解？
J Diabetes Complications. 2024 Aug;38(8):108800. doi: 10.1016/j.jdiacomp.2024.108800. Epub 2024 Jun 14.
10
The Effect of Sodium-Glucose Cotransporter Inhibitors on Renal Function as Adjunctive to Insulin in Adults with Type 1 Diabetes: An Updated Multilevel Meta-analysis of Randomized Controlled Trials.钠-葡萄糖协同转运蛋白抑制剂作为胰岛素辅助治疗对1型糖尿病成人肾功能的影响：随机对照试验的最新多水平荟萃分析
Diabetes Ther. 2024 Feb;15(2):521-532. doi: 10.1007/s13300-023-01523-0. Epub 2024 Jan 5.
Zotero 插件